AMERICAN ACADEMY OF NEUROLOGY

This year, the 75th annual meeting was a hybrid event. It was held in person in Boston and was available as a distinct virtual experience later in April.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

AMERICAN ACADEMY OF NEUROLOGY

This year, the 74th annual meeting is a hybrid event. It was held in person in Seattle and will be available as a distinct virtual experience later in April.

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

AMERICAN ACADEMY OF NEUROLOGY

 

The presentations downloaded using this platform are intended as an educational resource for legitimate scientific exchange and not for promotional use.

April 22-27 | Boston & Virtual

AAN 2023 Annual Meeting

April 02-07 | Seattle, April 24-26 | Virtual

AAN 2022 Annual Meeting

Archive List

AAN Annual Meeting

Final results of the SPECTRE study: real-world data giving an insight into the treatment of migraine patients with erenumab in Germany

Gaul C et. al; ePoster: P12.011

Efficacy and Safety of Erenumab 70 mg in Adult Patients with Chronic Migraine: Results From a Phase 3, Randomized, Double-blind, Placebo-controlled DRAGON Study

Wang SJ, et al; Oral presentation S31. 005

Long-term Safety and Tolerability of Erenumab in Episodic Migraine: A Pooled Analysis From Two Clinical Trials and Their Extension Phases

Ashina M, et al; ePoster P3.2-005

A Real-world, Observational Study of Erenumab for Migraine Prevention in Canadian Patients with Prior Prophylactic Treatment Failure

Becker W, et al; ePoster P10.2-002

Erenumab Versus Topiramate for the Prevention of Migraine: Results of a Post-hoc Efficacy Analysis

Ehrlich M, et al; ePoster P16.2-004

Effect of Erenumab on Patient-reported Outcomes in Patients with Episodic Migraine From Asia, the Middle East and Latin America: The EMPOwER Study

Wang SJ, et al; ePoster P16.2-006

Real-world Healthcare Costs and Resource Utilization Among Patients Treated with Erenumab in the United States: A Retrospective Claims Database Study

Tepper SJ, et al; ePoster P16.7-003

Three-year Efficacy and Safety of Erenumab in Participants with Episodic Migraine and 2–4 Prior Preventive Treatment Failures: Results From the LIBERTY Study

Reuter U, et al; Virtual poster

2021 Presentations

Consistent efficacy and safety of erenumab over time in patients with episodic migraine who completed a 5-year, open-label extension study

Ashina M, et al; ePoster: P10.001

Comparative effectiveness of erenumab versus oral preventive medications among migraine patients: A US claims database study

Tepper S, et al; ePoster: P10.032

Risk of hypertension in erenumab-treated patients with migraine in clinical trials and in the post marketing setting

Dodick D, et al; ePoster: P10.044

Design and population characteristics of patients treated with monoclonal antibody erenumab for assessment of long-term safety and tolerability and frequency of drug holidays in Germany (APOLLON)

Ortler S, et al; ePoster: P10.047

2020 Presentations

Long-term efficacy of erenumab in chronic migraine (CM) patients with or without acute medication overuse (AMO)

S. Tepper, R. B. Lipton, S. Silberstein, D. Kudrow, M. Ashina, U. Reuter, D. Dodick, F. Zhang, S. Cheng, D. D. Mikol
Poster number: P2.6-002

First-hand impressions of the monoclonal antibody erenumab from treated patients in Germany

C. Gaul, H. Israel-Willner, M. Koch, K. Schuh
Poster number: P3.6-001

First real-world evidence data for the monoclonal antibody erenumab from specialized migraine centers in Germany

A. Straube, P. Stude, K. Schuh, M. Koch
Poster number: P3.6-005

Sustained efficacy and long-term safety of erenumab in patients with episodic migraine: 4+ year results of a 5-year, open-label treatment period

M. Ashina, P. J. Goadsby, U.Reuter, S. Silberstein,D.W.Dodick, D. E. Chou, J. Klatt, F. Xue, F. Zhang, S. Cheng, D. D. Mikol
Oral presentation: S8.001

Benefit of migraine prevention with erenumab in patients receiving background standard-of-care acute treatment

A. Starling, S. Tepper, C. Bernstein, J. Ailani, F. Zhang, G. Paiva da Silva Lima, D. E. Chou
Oral presentation: S8.006

Safety and tolerability of erenumab in older migraine patients: A subgroup analysis of randomised trials

C. Lampl, J. Snellman, S. Ritter, J. Klatt
Poster number: P7.6-004

Changes in acute migraine-specific medications after initiating erenumab: Results from a real-world retrospective cohort study in the United States

SD. M. Hines, S. Shah, J. K. Multani,R. L. Wade, D. C. Buse, M. E. Bensink
Poster number: P11.6-001

Impact of an employer-provided migraine coaching program on burden and patient engagement: Results from interim analysis

L. Schaetz, T. Rimner, P. Pathak, J. Fang, D. Chandrasekhar, J. Mueller
Oral presentation: S47.004

Migraine polygenic risk score is associated with severity of migraine: Analysis of genotypic data from four placebo-controlled trials of erenumab

D.D. Mikol, H. Picard, J. Klatt, A. Wang, C. Peng, K. Stefansson
Oral presentation: S47.006

Economic burden increased with number of treatment failure in migraine patients: A retrospective claims database analysis in the united states

L. Newman, J. Huels, P. Vo, L. Zhou, C. Lopez Lopez, A. Cheadle, M. Olson, J. Fang
Oral presentation: S47.009

Cardiovascular safety of erenumab in patients with migraine and aura

M. Ashina, P. J Goadsby, D.W.Dodick, S. J Tepper, F. Xue, F. Zhang, J. Olearczyk, G. Paiva da Silva Lima
Oral presentation: S58.010



Click here for all published abstracts

click here

Click here for all published abstracts

click here

Click here for all published abstracts

2021 2020

For more details please visit:

AAN 2020 Science Highlights
Erenumab is co-developed by Novartis and Amgen

Cookie Settings
© Copyright 2023 Novartis Pharma AG